Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

被引：22

作者：

Cortellini, Alessio ^{[1
,2
]}

Cannita, Katia ^{[3
]}

Tiseo, Marcello ^{[4
,5
]}

Cortinovis, Diego L. ^{[6
]}

Aerts, Joachim G. J., V ^{[7
]}

Baldessari, Cinzia ^{[8
]}

Giusti, Raffaele ^{[9
]}

Ferrara, Miriam G. ^{[10
,11
]}

D'Argento, Ettore ^{[10
]}

Grossi, Francesco ^{[12
]}

Guida, Annalisa ^{[13
]}

Berardi, Rossana ^{[14
]}

Morabito, Alessandro ^{[15
]}

Genova, Carlo ^{[16
]}

Antonuzzo, Lorenzo ^{[17
]}

Mazzoni, Francesca ^{[17
]}

De Toma, Alessandro ^{[18
]}

Signorelli, Diego ^{[18
,19
]}

Gelibter, Alain ^{[20
]}

Targato, Giada ^{[21
]}

Rastelli, Francesca ^{[22
]}

Chiari, Rita ^{[23
]}

Rocco, Danilo ^{[24
]}

Gori, Stefania ^{[25
]}

De Tursi, Michele ^{[26
]}

Mansueto, Giovanni ^{[27
]}

Zoratto, Federica ^{[28
]}

Filetti, Marco ^{[9
]}

Bracarda, Sergio ^{[29
]}

Citarella, Fabrizio ^{[30
]}

Russano, Marco ^{[30
]}

Cantini, Luca ^{[7
,14
]}

Nigro, Olga ^{[31
]}

Buti, Sebastiano ^{[5
]}

Minuti, Gabriele ^{[32
]}

Landi, Lorenza ^{[32
]}

Ricciardi, Serena ^{[33
]}

Migliorino, Maria R. ^{[33
]}

Natalizio, Salvatore ^{[34
]}

Simona, Carnio ^{[35
]}

De Filippis, Marco ^{[35
]}

Metro, Giulio ^{[36
]}

Adamo, Vincenzo ^{[37
]}

Russo, Alessandro ^{[37
]}

Spinelli, Gian P. ^{[38
]}

Di Maio, Massimo ^{[39
,40
]}

Banna, Giuseppe L. ^{[41
]}

Friedlaender, Alex ^{[42
]}

Addeo, Alfredo ^{[42
]}

Pinato, David J. ^{[2
,43
]}

机构：

[1] Univ LAquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[2] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Div Canc, London, England

[3] St Salvatore Hosp, Med Oncol, Laquila, Italy

[4] Univ Parma, Dept Med & Surg, Parma, Italy

[5] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[6] Osped San Gerardo, Med Oncol, Monza, Italy

[7] Erasmus MC, Dept Pulm Dis, Rotterdam, Netherlands

[8] AOU Policlin Modena, Dipartimeto Oncol Ematol, Modena, Italy

[9] St Andrea Hosp, Med Oncolgy, Rome, Italy

[10] Fdn Policlin Univ Gemelli, Comprehens Canc Ctr, IRCCS, Rome, Italy

[11] Univ Cattolica Sacro Cuore, Dept Translat Med & Surg, Romae, Lazio, Italy

[12] Fdn IRCCS CaGranda Osped Maggiore Policlin, Med Oncol Unit, Milan, Italy

[13] Azienda Osped Santa Maria, Dept Oncol, Terni, Italy

[14] Univ Politecn Marche, Osped Riuniti Ancona, Oncol Clin, Ancona, Italy

[15] Ist Nazl Tumori, IRCCS, Thorac Med Oncol, Fdn G Pascale, Naples, Italy

[16] Osped Policlin San Martino, Lung Canc Unit, IRCCS, Genoa, Italy

[17] Careggi Univ Hosp, Dept Oncol, Florence, Italy

[18] Ist Nazl Tumori, Dept Med Oncol, Fdn IRCCS, Milan, Italy

[19] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy

[20] Sapienza Univ Rome, Policlin Umberto I, Med Oncol B, Rome, Italy

[21] Univ Hosp Santa Maria Misericordia, Dept Oncol, Udine, Italy

[22] Med Oncol, Fermo Area Vasta 4, Fermo, Italy

[23] Osped Riuniti Padova Sud Madre Teresa Calcutta, Med Oncol, Monselice, Italy

[24] Monaldi Hosp, Pneumo Oncol Unit, Naples, Italy

[25] Osped Sacro Cuore Don Calabria, IRCCS, Oncol Unit, Negrar, VR, Italy

[26] Oral & Biotechnol Sci Univ G DAnnunzio, Dept Med, Chieti, Italy

[27] Spaziani Hosp, Med Oncol, Frosinone, Italy

[28] Santa Maria Goretti Hosp, Med Oncol, Latina, Italy

[29] Azienda Osped Santa Maria Terni, Struttura Complessa Oncol Med & Traslaz, Terni, Italy

[30] Campus Biomed Univ, Med Oncol, Rome, Italy

[31] ASST Sette Laghi, Med Oncol, Varese, Italy

[32] AUSL Romagna, Dept Oncol & Hematol, Ravenna, Italy

[33] St Camillo Forlanini Hosp, Pneumo Oncol Unit, Rome, Italy

[34] Univ Modena & Raggio Emilia, Dipartimento Oncol Ematol, Modena, Italy

[35] Univ Turin, San Luigi Hosp, Dept Oncol, Orbassano, TO, Italy

[36] Azienda Osped Perugia, Dept Med Oncol, Santa Maria Misericordia Hosp, Perugia, Italy

[37] Univ Messina, AO Papardo & Dept Human Pathol, Med Oncol, Messina, Italy

[38] Univ Rome Sapienza, UOC Terr Oncol Aprilia, AUSL Latina, Aprilia, Italy

[39] Univ Turin, Dept Oncol, Turin, Italy

[40] AO Ordine Mauriziano, Med Oncol, Turin, Italy

[41] Portsmouth Hosp Univ NHS Trust, Portsmouth, Hants, England

[42] Univ Hosp Geneva, Oncol Dept, Geneva, Switzerland

[43] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2021年 / 148卷

关键词：

Non-small cell lung cancer; Immunotherapy; PD-L1; Pembrolizumab; Performance status; Post-progression; Radiotherapy; Radiation therapy; CELL LUNG-CANCER; IMMUNE-CHECKPOINT INHIBITORS; SALVAGE CHEMOTHERAPY; RESPONSE RATES; IMMUNOTHERAPY; RADIOTHERAPY; ASSOCIATION; ASSAYS;

D O I：

10.1016/j.ejca.2021.02.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Treatment sequencing with first-line immunotherapy, followed by second-line chemotherapy, is still a viable option for NSCLC patients with PD-L1 expression >50%. Methods: We evaluated post-progression treatment pathways in a large real-world cohort of metastatic NSCLC patients with PD-L1 expression > 50% treated with first-line pembrolizumab monotherapy. Results: Overall, 974 patients were included. With a median follow-up of 22.7 months (95%CI: 21.6-38.2), the median overall survival (OS) of the entire population was 15.8 months (95% CI: 13.5-17.5; 548 events). At the data cutoff, among the 678 patients who experienced disease progression, 379 (55.9%) had not received any further treatment, and 359 patients (52.9%) had died. Patients who did not receive post-progression therapies were older (p = 0.0011), with a worse ECOG-PS (p < 0.0001) and were on corticosteroids prior to pembrolizumab (p = 0.0024). At disease progression, 198 patients (29.2%) received a switched approach and 101 (14.9%) received pembrolizumab ByPD either alone (64 [9.4%]) or in combination with local ablative treatments (37 [5.5%]) (LATs). After a random-case control matching according to ECOG-PS, CNS metastases, bone metastases, and (previous) best response to pembrolizumab, patients receiving pembrolizumab ByPD plus LATs were confirmed to have a significantly longer post-progression OS compared to patients receiving pembrolizumab ByPD alone 13.9 months versus 7.8 months (p = 0.0179) 241 patients (35.5%) among the 678 who had experienced PD, received a second-line systemic treatment (regardless of previous treatment beyond PD). As compared to first-line treatment commencement, patients' features at the moment of second-line initiation showed a significantly higher proportion of patients aged under 70 years (p = 0.0244), with a poorer ECOG-PS (p < 0.0001) and having CNS (p = 0.0001), bone (p = 0.0266) and liver metastases (p = 0.0148). Conclusions: In the real-world scenario NSCLC patients with PD-L1 expression >50% treated with first-line single-agent pembrolizumab achieve worse outcomes as compared to the Keynote-024 trial. Poor post-progression outcomes are major determinants of the global results that should be considered when counselling patients for first-line treatment choices. (c) 2021 Elsevier Ltd. All rights reserved.

引用

页码：24 / 35

页数：12

共 50 条

[11] Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression (HOT/NJLCG2001 secondary report)
Tateishi, Kazunari
Mizugaki, Hidenori
Ikezawa, Yasuyuki
Morita, Ryo
Yokoo, Keiki
Sumi, Toshiyuki
Kikuchi, Hajime
Kitamura, Yasuo
Nakamura, Atsushi
Kobayashi, Maki
Aso, Mari
Kimura, Nozomu
Yoshiike, Fumiaki
Furuta, Megumi
Tanaka, Hisashi
Sekikawa, Motoki
Hashiya, Tsutomu
Fujita, Yuka
Oizumi, Satoshi
ANNALS OF ONCOLOGY, 2023, 34 : S1394 - S1394
[12] Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
Velcheti, Vamsidhar
Hu, Xiaohan
Li, Yeran
El-Osta, Hazem
Pietanza, M. Catherine
Burke, Thomas
CANCERS, 2022, 14 (04)
[13] Real-world data of first-line treatment with pembrolizumab for highly PD-L1 expressing NSCLC (HOT/NJLCG2001)
Nakamura, A.
Mizugaki, H.
Ikezawa, Y.
Morita, R.
Tateishi, K.
Yokoo, K.
Sumi, T.
Kikuchi, H.
Kitamura, Y.
Morita, M.
Aso, M.
Tsukita, Y.
Yoshiike, F.
Furuta, M.
Tanaka, H.
Sekikawa, M.
Hachiya, T.
Nakamura, K.
Yokouchi, H.
ANNALS OF ONCOLOGY, 2021, 32 : S1008 - S1008
[14] Long-term real- world outcomes of first-line (1L) pembrolizumab (pembro) monotherapy in PD-L1 ≥50% metastatic NSCLC.
Velcheti, Vamsidhar
Hu, Xiaohan
Piperdi, Bilal
Yang, Lingfeng
Burke, Thomas A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[15] Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France
Perol, M.
Filleron, T.
Quantin, X.
Chouaid, C.
Valette, C. Audigier
Lena, H.
Kaderbhai, C.
Fabre, C.
Santorelli, M.
Bensimon, L.
Burke, T.
Couch, D.
Nguyen, E.
Courtinard, C.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S757 - S758
[16] Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
Doubre, Helene
Greillier, Laurent
Justeau, Gregoire
Ricordel, Charles
Swalduz, Aurelie
Curcio, Hubert
Bylicki, Olivier
Auliac, Jean-Bernard
Guisier, Florian
Bigay-Game, Laurence
Bernardi, Marie
Pinsolle, Julian
Amrane, Karim
Decroisette, Chantal
Descourt, Renaud
Chouaid, Christos
Geier, Margaux
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (16) : 15095 - 15102
[17] Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
Hélène Doubre
Laurent Greillier
Grégoire Justeau
Charles Ricordel
Aurélie Swalduz
Hubert Curcio
Olivier Bylicki
Jean-Bernard Auliac
Florian Guisier
Laurence Bigay-Game
Marie Bernardi
Julian Pinsolle
Karim Amrane
Chantal Decroisette
Renaud Descourt
Christos Chouaid
Margaux Geier
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 15095 - 15102
[18] Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids
Frost, Nikolaj
Kollmeier, Jens
Misch, Daniel
Vollbrecht, Claudia
Grah, Christian
Matthes, Burkhard
Pultermann, Dennis
Olive, Elisabeth
Raspe, Matthias
Ochsenreither, Sebastian
von Laffert, Maximilian
Suttorp, Norbert
Witzenrath, Martin
Grohe, Christian
CLINICAL LUNG CANCER, 2021, 22 (05) : 411 - 422
[19] Real-world multicentre cohort of 1L pembrolizumab alone or in combination with platinum-based chemotherapy in NSCLC PD-L1 ≥ 50%
Pons-Tostivint, E.
Hulo, P.
Guardiolle, V.
Bodot, L.
Rabeau, A.
Porte, M.
Hiret, S.
Demontrond, P.
Curcio, H.
Boudoussier, A.
Veillon, R.
Mayenga, M.
Dumenil, C.
Gourraud, P-A.
Mazieres, J.
Bennouna, J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1060 - S1060
[20] Real-world data on efficacy and safety of pembrolizumab in the first-line treatment of metastatic lung cancer in patients with PD-L1 expression >0% - a single center experience
Cvijic, T.
Canjko, I.
Tomas, I.
Kralik, K.
Peric, L.
Kotromanovic, D.
Dupan, Z. Krivdic
Peic, A. Kovac
Mimica, S.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (19) : 9213 - 9225

← 1 2 3 4 5 →

Post-progression outcomes of NSCLC patients with PD-L1 expression &gt; 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study